



[wherein, R<sup>1</sup> is hydrogen, lower alkyl or acyl, R<sup>2</sup> is hydrogen or acyl, R<sup>3</sup> is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), and R<sup>4</sup> is heterocyclic group which may have suitable substituent(s), heterocyclic (lower) alkyl, heterocyclic thio or heterocyclic sulfinyl] or a salt thereof.


4. (Amended) An organ preservative of claim 1, wherein the MAPK inhibitor and/or the inhibitor on the production of interleukin-1 (IL-1) and/or the inhibitor on the production of tumor necrosis factor (TNF) is/are a compound represented by the formula:



[wherein, R<sup>1</sup> is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), R<sup>2</sup> is aryl which may have suitable substituent(s) or a heterocyclic group which may have suitable substituent(s), and Y a bivalent radical selected from




and



(in which ----- is a single bond or a double bond), each of which may have suitable substituent(s)] or a salt thereof.

5. (Amended) An organ preservative of claim 1, wherein a MAPK inhibitor and/or an inhibitor on the production of interleukin-1 (IL-1) and/or the inhibitor on the production of tumor necrosis factor (TNF) is/are a compound represented by the formula:



[wherein, R<sup>1</sup> is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), R<sup>2</sup> is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), R<sup>3</sup> is hydrogen or acyl, R<sup>4</sup> is hydrogen, lower alky, cyclo (lower) alkyl, cyclo (lower) alkyl-(lower) alkyl, carboxy (lower) alkyl, protected carboxy(lower)alkyl, ar (lower)alkyl which may have suitable substituent(s),